Why I think AstraZeneca should be in your 2019 share portfolio

AstraZeneca plc (LON: AZN) has multiple positive catalysts and I see a buying opportunity right now.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Amidst the broader market volatility, investors are likely to be more selective as to which stocks to add to their portfolio in 2019. If you believe in holding shares for the long term, I’d suggest that you take a closer look at AstraZeneca (LSE: AZN) shares as part of your healthcare portfolio.

Year-to-date, AZN’s share price is up about 10%, despite the market volatility. Let’s take a closer look at the fundamentals that are supporting the strong performance of the shares.

Robust earnings

The company is one of the largest, most innovative pharmaceutical companies globally. Its latest earnings release in November showed a strong balance sheet and positive outlook going into 2019. Chief executive Pascal Soriot confirmed expectations that the company is to grow both organically and possibly through acquisitions — which it can afford thanks to its cash flow. Analysts are now looking for a 10%+ earnings per share (EPS) increase in the New Year.

In addition to a robust balance sheet and growing profits, the dividend yield of 3.3% makes it a worthwhile pick for risk-averse income investors who know that they can compound their returns through reinvesting dividends.

Broad pipeline

The firm’s R&D and manufacturing focus lies in cancer (oncology), cardiovascular, gastrointestinal, infection, neuroscience, and respiratory, and inflammation segments. Lynparza, Tagrisso, and Brilinta are new drugs that analysts expect to contribute to the top line.

It has several prospective drug launches in the cancer, metabolism and respiratory areas, such as Imfinzi — prescribed against lung cancer. And it is exploring new avenues for growth too. In November it announced a partnership with the Belgian Biocartis Group — a molecular diagnostics company  for obtaining lung cancer diagnostic biomarker results. Its cancer focus has seen it selling its anaesthetics medicines, as well as its antibiotics division, to raise cash for what it sees as its core areas.

What could derail the shares?

On December 11, the UK parliament will vote on the Prime Minister’s proposed Brexit deal. If the government loses the vote, the country will face more uncertainty — and that would be likely to that negatively affect the FTSE, the pound and possibly AstraZeneca shares, in spite of its strength so far this year.

Like most large pharmaceutical companies, it also faces continuous risks from generic drugs competition, especially for its Nexium, Crestor, and Seroquel brands. That means some investors may see a P/E ratio of 25 as a bit rich. Personally, I think its pipeline is strong enough to offset any threat to the bottom line.

If the share price does suffer in 2019, I would expect to see yet another takeover bid from Pfizer. In 2014, the board rejected a £55-per-share offer made by the US company but AZN’s drive to become a leader in oncology treatments means many analysts both in the UK and the US would not be surprised to see yet another offer from its erstwhile suitor.

The bottom line on the shares

AstraZeneca is a fundamentally sound company with a good track record of R&D and commercialisation success – two factors that translate into a strong balance sheet and double-digit bottom line growth next year. With a beta of around 0.65 (meaning it is one of those stocks that are less volatile than the broader market), I think it could be a strong pick for another downleg or a possible bear market in 2019.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

tezcang has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

2 industry-leading value stocks investors should consider buying

These value stocks are at the top of their respective industries, and look like current bargains with the potential to…

Read more »

Black father and two young daughters dancing at home
Investing Articles

Just released: our 3 top small-cap stocks to buy before August [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Investing Articles

If I’d put £5k in a FTSE 100 index fund 10 years ago, here’s what I’d have now!

Charlie Carman explores the performance of the FTSE 100 index over the past decade and the merits of passive versus…

Read more »

Investing Articles

£15K stashed away? I could turn that into a second income worth £49 a day!

This Fool explains how she would look to gain a second income through investing in UK stocks, and the steps…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

With the Apple share price near an all-time high, would I be crazy to buy more?

After touching all-time highs yesterday, the Apple share price is on a roll. But is there still enough growth ahead…

Read more »

Investing Articles

Nvidia stock has fallen 13% from its 52-week high! What next?

Our writer explains why Nvidia stock has dipped recently and highlights some risks associated with investing in the AI leader…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

The AstraZeneca share price is up 88% in 5 years, but is it just getting started?

The AstraZeneca share price has had a great few years, as acquisitions and clinical trials delighted shareholders. So is there…

Read more »

Investing Articles

Here’s why I’m watching the Anglo American share price

The mining sector has always interested investors. But after a flat few years, I'm wondering what's next for the Anglo…

Read more »